Lv7
3608 积分 2021-07-21 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
22天前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
1个月前
已完结
Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma
1个月前
已完结
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer
1个月前
已完结
Reading Between the Lines: Circulating Tumor DNA Dynamics Illuminate Immunotherapy Outcomes in Lung Squamous Cell Carcinoma
2个月前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
2个月前
已完结
GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma
2个月前
已完结
MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists
3个月前
已完结
皖公网安备34019202002308
